01 吉利德科学公司的新型HIV抗病毒药物来那帕韦 (lenacapavir)在第二个关键3期临床试验中显示出99.9%的受试者未感染HIV，一年两次给药的治疗方案解决了HIV感染者需要终身服药的问题。

The drug, lenacapavir PrEP, could benefit tens of millions of people at high risk of infection The post ACT UP London protest ...

吉利德科学公司（NASDAQ:GILD）在竞争对手临床试验受挫后，继续保持其在肿瘤市场的强劲地位。全球投资银行公司Jefferies重申了对吉利德科学公司的信心，给予"买入"评级，目标价格维持在95.00美元。

在过去的40多年里，人类一直在与艾滋病进行着不懈的斗争。随着医学技术的进步，HIV已经从一种致命的疾病转变为一种可预防、可控制的慢性病。根据联合国艾滋病规划署2024年7月发布的最新报告，截至2023年底，全球约有3990万HIV感染者。在2023年，新增了大约130万HIV感染者，同时有63万人因HIV相关疾病去世。报告指出，向HIV感染者推广治疗方面取得了显著进展，目前超过75%的感染者，即3 ...

Jaipur: The state health department has declared five medicine samples as substandard following tests and analysis.

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked ...

Ending Acquired Immune Deficiency Syndrome (AIDS) as a public health threat here by 2030 will take much effort as it will all around the world. The key, ...

There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...

It was a busy week for the biotech sector with a lot of important data readouts at the European Society for Medical Oncology ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

The fund invests more than S$6.4 billion a year to fight tuberculosis, malaria, and HIV. Read more at straitstimes.com.

The ministry of Health has announced the administration of the first dose of Cabotegravir (Cab-LA) as part of Uganda’s ...